Medical device company Meacor has closed a $15m Series A funding round, a significant step forward in the development of its transcatheter heart valve repair technology.
This investment will fuel the advancement of Meacor’s Cryocinch system, which aims to offer a new minimally invasive treatment for mitral and tricuspid valve regurgitation.
Related: Atraverse wins FDA nod for left-heart access device, raises $12.5M
The system utilises on-demand cryoadhesion to address cardiac motion, allowing for the precise and reproducible placement of interconnected anchors along the valve annulus.
This technology is poised to provide an effective solution to halt regurgitation, potentially offering patients numerous advantages over conventional open-heart surgery, such as shorter recovery times, reduced risks of complications, and lower costs.
Meacor CEO and co-founder Toufic Azar said: “This is a pivotal moment for Meacor. This funding round underscores the potential of our technology to enhance valvular heart repair.
“With this capital, we can strategically grow our team, to rapidly achieve critical milestones while maintaining our lean and efficient R&D [research and development] and clinical operations.”
Furthermore, Meacor has appointed Dr Azeem Latib and Dr Susheel Kodali as senior clinical advisers.
Rick Geoffrion, with a track record of success in the interventional cardiology device sector, has joined Meacor as a senior business advisor.
Meacor co-founder, president, and chief medical officer, and McGill University cardiothoracic surgeon Dr Renzo Cecere said: “Transcatheter annuloplasty remains an unmet frontier in the management of valvular regurgitation, which to date has been limited to valve replacement and edge-to-edge repair.
“Meacor’s technology promises a reproducible, robust, and efficient procedure. Cryoadhesion is designed to enhance ease of positioning and stabilisation of the annulus, providing significant advantages for both doctors and patients.”
